ATE459364T1 - Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren - Google Patents
Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumorenInfo
- Publication number
- ATE459364T1 ATE459364T1 AT04809987T AT04809987T ATE459364T1 AT E459364 T1 ATE459364 T1 AT E459364T1 AT 04809987 T AT04809987 T AT 04809987T AT 04809987 T AT04809987 T AT 04809987T AT E459364 T1 ATE459364 T1 AT E459364T1
- Authority
- AT
- Austria
- Prior art keywords
- tumors
- microtubule
- spores
- agents
- found
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 238000002648 combination therapy Methods 0.000 title 1
- 102000029749 Microtubule Human genes 0.000 abstract 5
- 108091022875 Microtubule Proteins 0.000 abstract 5
- 210000004688 microtubule Anatomy 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002008 hemorrhagic effect Effects 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 231100000782 microtubule inhibitor Toxicity 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 abstract 1
- 229960002066 vinorelbine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/842—Clostridium
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51292303P | 2003-10-22 | 2003-10-22 | |
| PCT/US2004/034625 WO2005039492A2 (en) | 2003-10-22 | 2004-10-21 | Improved combination bacteriolytic therapy for the treatment of tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE459364T1 true ATE459364T1 (de) | 2010-03-15 |
Family
ID=34520062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04809987T ATE459364T1 (de) | 2003-10-22 | 2004-10-21 | Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US8007782B2 (de) |
| EP (1) | EP1675465B1 (de) |
| AT (1) | ATE459364T1 (de) |
| DE (1) | DE602004025834D1 (de) |
| WO (1) | WO2005039492A2 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009017908A1 (de) * | 2009-04-17 | 2010-10-21 | Kist-Europe Forschungsgesellschaft Mbh | Vektor für den Transport von mikrobiologischen Organismen zu Krankheitsherden |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| JP6125041B2 (ja) | 2013-01-02 | 2017-05-10 | デコイ バイオシステムズ インコーポレイテッドＤｅｃｏｙ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． | 細菌を用いた癌治療用組成物およびその製造のための菌の使用 |
| PL2968440T3 (pl) | 2013-03-15 | 2019-12-31 | Zymeworks Inc. | Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania |
| US12433920B2 (en) | 2013-03-29 | 2025-10-07 | Biomed Valley Discoveries, Inc. | C. novyi for the treatment of solid tumors in non-human animals |
| US10617723B2 (en) | 2013-03-29 | 2020-04-14 | Biomed Valley Discoveries, Inc. | C. novyi for the treatment of solid tumors in humans |
| AU2014373640B2 (en) | 2013-12-27 | 2018-08-30 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
| RU2729194C2 (ru) | 2013-12-27 | 2020-08-05 | Займворкс Инк. | Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов |
| EP3149024B9 (de) | 2014-05-28 | 2021-10-27 | Agensys, Inc. | Zytotoxische dolaproin-dolaisoleuin-peptid-derivate zur behandlung von krebs |
| US20160250351A1 (en) | 2014-06-13 | 2016-09-01 | Mayo Foundation For Medical Education And Research | Treating Lymphomas |
| EP3834889A1 (de) | 2014-06-16 | 2021-06-16 | Mayo Foundation for Medical Education and Research | Behandlung von myelomen |
| EP2998000A1 (de) * | 2014-09-16 | 2016-03-23 | University College Cork-National University of Ireland, Cork | Kombinationstherpie bei krebs |
| AU2015318556C1 (en) | 2014-09-17 | 2021-01-07 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| WO2016123313A1 (en) | 2015-01-29 | 2016-08-04 | Oxyrase, Inc. | Methods for inhibiting tumor growth |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11305020B2 (en) | 2016-03-21 | 2022-04-19 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| EP3432928A4 (de) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | Verfahren zur verbesserung des therapeutischen index für ein chemotherapeutikum |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CN109890419A (zh) | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
| CA3035377A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Nanoparticle compositions for targeting t-cell cancers |
| EP3509643A1 (de) * | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-bindende wirkstoffzusammensetzungen und verfahren zur verwendung und herstellung davon |
| WO2018048816A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| GB201801977D0 (en) * | 2018-02-07 | 2018-03-28 | Knauf Insulation Doo Skofja Loka | Recycling |
| CN111001014B (zh) * | 2019-12-12 | 2022-04-22 | 四川大学华西医院 | 一种基于固定细菌做载体的抗肿瘤药物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688517A (en) * | 1993-01-29 | 1997-11-18 | Napro Biotherapeutics, Inc. | Method for assessing sensitivity of tumor cells to cephalomannine and 10-deacetyltaxol |
| US5554638A (en) * | 1993-05-24 | 1996-09-10 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
| ES2227667T3 (es) * | 1996-02-02 | 2005-04-01 | Zentaris Gmbh | Metodo para la inactivacion de proteinas de la subfamilia ras y agentes para ello. |
| WO2003045153A1 (en) * | 2001-11-21 | 2003-06-05 | The Johns Hopkins University | Combination bacteriolytic therapy for the treatment of tumors |
| ITMI20012497A1 (it) * | 2001-11-28 | 2003-05-28 | Agriplast S N C | Perfezionamento nei tubi per l'irrigazione a goccia |
| WO2005039491A2 (en) * | 2003-10-22 | 2005-05-06 | The John Hopkins University | Certain improved combination bacteriolytic therapy for the treatment of tumors |
-
2004
- 2004-10-21 AT AT04809987T patent/ATE459364T1/de not_active IP Right Cessation
- 2004-10-21 WO PCT/US2004/034625 patent/WO2005039492A2/en not_active Ceased
- 2004-10-21 DE DE602004025834T patent/DE602004025834D1/de not_active Expired - Lifetime
- 2004-10-21 US US10/568,765 patent/US8007782B2/en active Active
- 2004-10-21 EP EP04809987A patent/EP1675465B1/de not_active Expired - Lifetime
-
2011
- 2011-08-05 US US13/198,850 patent/US8613917B2/en not_active Expired - Fee Related
-
2013
- 2013-12-16 US US14/106,987 patent/US9572843B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20070148135A1 (en) | 2007-06-28 |
| WO2005039492A3 (en) | 2005-06-30 |
| DE602004025834D1 (de) | 2010-04-15 |
| US20110311500A1 (en) | 2011-12-22 |
| EP1675465A2 (de) | 2006-07-05 |
| US8007782B2 (en) | 2011-08-30 |
| US20140328813A1 (en) | 2014-11-06 |
| US9572843B2 (en) | 2017-02-21 |
| US8613917B2 (en) | 2013-12-24 |
| WO2005039492A9 (en) | 2005-06-02 |
| EP1675465B1 (de) | 2010-03-03 |
| WO2005039492A2 (en) | 2005-05-06 |
| EP1675465A4 (de) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE459364T1 (de) | Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren | |
| Renschler | The emerging role of reactive oxygen species in cancer therapy | |
| Sugarbaker | Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy | |
| Utsumi et al. | Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo | |
| Wilde et al. | Autophagy in cancer: a complex relationship | |
| Liu et al. | Protecting the normal in order to better kill the cancer | |
| Dick et al. | Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy | |
| Ma et al. | Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer | |
| Dorie et al. | Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine | |
| Qu et al. | Bexarotene: a promising anticancer agent | |
| Luo et al. | Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers | |
| Kapper et al. | Targeting ferroptosis in ovarian cancer: novel strategies to overcome chemotherapy resistance | |
| He et al. | Potent inhibition of gastric cancer cells by a natural compound via inhibiting TrxR1 activity and activating ROS-mediated p38 MAPK pathway | |
| Ho et al. | Antimetastatic potentials of Dioscorea nipponica on melanoma in vitro and in vivo | |
| Roomi et al. | Inhibition of pulmonary metastasis of melanoma B16FO cells in C57BL/6 mice by a nutrient mixture consisting of ascorbic acid, lysine, proline, arginine, and green tea extract | |
| Douple | The use of platinum chemotherapy to potentiate radiotherapy | |
| NO20050793L (no) | Anvendelse av urease for inhibering av kreftcellevekst | |
| WO2005039491A3 (en) | Certain improved combination bacteriolytic therapy for the treatment of tumors | |
| Masunaga | Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells | |
| Friedmann et al. | Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer | |
| Engblom et al. | Carboplatin–paclitaxel‐and carboplatin–docetaxel‐induced cytotoxic effect in epithelial ovarian carcinoma in vitro | |
| Volz et al. | Modulation of tumor‐induced lethality after pneumoperitoneum in a mouse model | |
| Watanabe et al. | Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents | |
| Sogno et al. | Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. | |
| Watanabe et al. | Antivascular effects of TZT‐1027 (Soblidotin) on murine Colon26 adenocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |